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Original ArticleTiotropium Respimat Add-on Is Efficacious in
Symptomatic Asthma, Independent of T2
PhenotypeThomas B. Casale, MDa, Eric D. Bateman, MDb, Mark Vandewalker, MDc, J. Christian Virchow, MDd,
Hendrik Schmidt, PhDe, Michael Engel, MDf, Petra Moroni-Zentgraf, MDg, and Huib A.M. Kerstjens, MDh Tampa, Fla;
Cape Town, South Africa; Columbia, Mo; Rostock, Biberach an der Riss, and Ingelheim am Rhein, Germany; Sydney, NSW, Australia;
and Groningen, The NetherlandsWhat is already known about this topic? Current research in asthma is directed toward identifying endotypes that
predict response to asthma therapies, including biologics. T2high and T2low phenotypes are deﬁned by their differing in-
ﬂammatory cell composition and biomarkers.
What does this article add to our knowledge? This exploratory subgroup analysis of 4 large randomized trials suggests
that the efﬁcacy of the long-acting anticholinergic tiotropium is not predicted by T2high or T2low proﬁle, deﬁned by IgE level
or eosinophil count, in patients with asthma.
How does this study impact current management guidelines? Our data suggest that patients being considered for the
addition of tiotropium Respimat for symptomatic asthma and/or for the prevention of asthma exacerbations do not require
prior phenotyping by T2 status.BACKGROUND: Adding tiotropium to existing inhaled
corticosteroid (ICS) maintenance therapy with or without a
long-acting b2-agonist (LABA) has been shown to be beneﬁcial
in patients with symptomatic asthma.
OBJECTIVE: To assess whether responses to tiotropium
Respimat add-on therapy were inﬂuenced by patients’ T2 status.
METHODS: In this exploratory study, data from 4 phase III
trials were analyzed: once-daily tiotropium 5 mg or placebo as
add-on to ICS D LABA (PrimoTinA-asthma; 2 replicate trials;
NCT00772538/NCT00776984; n[ 912); once-daily tiotropium
5 mg or 2.5 mg, twice-daily salmeterol 50 mg, or placebo as add-on
to ICS (MezzoTinA-asthma; 2 replicate trials; NCT01172808/aDivision of Allergy and Immunology, Morsani College of Medicine, University of
South Florida, Tampa, Fla
bDivision of Pulmonology, Department of Medicine, University of Cape Town,
Cape Town, South Africa
cClinical Research of the Ozarks, Columbia, Mo
dUniversity Clinic Rostock, Interdiszplinäre Internistische Intensivstation, Zentrum
für Innere Medizin, Medizinische Klinik I, Rostock, Germany
eGlobal Biometrics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co.
KG, Biberach an der Riss, Germany
fTA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingel-
heim am Rhein, Germany
gMedical Department, Boehringer Ingelheim Pty Ltd, Sydney, NSW, Australia
hDepartment of Pulmonary Medicine, University Medical Center Groningen, Uni-
versity of Groningen, Groningen, The Netherlands
This work was supported by Boehringer Ingelheim. The sponsor was involved in the
study design, analysis, interpretation, and writing of the manuscript, and the de-
cision to submit the manuscript for publication in conjunction with the authors.
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of these studies have been reported previously. Here, further
exploratory subgroup analyses were performed to study whether
these coprimary end points were inﬂuenced by serum IgE levels,
blood eosinophil counts, and clinician judgment of allergic
asthma. In addition, for the continuous parameters, namely, IgE
and blood eosinophils, their inﬂuence on the treatment effect was
modeled over the whole range of values.
RESULTS: Tiotropium was efﬁcacious in improving peak FEV1
within 3 hours postdose and trough FEV1, independent of T2
status. Tiotropium signiﬁcantly reduced the risk of severe
asthma exacerbations and asthma worsening, independent of T2support and consultancy fees and is on the speaker’s bureau for Boehringer
Ingelheim; is on the AstraZeneca Asthma & chronic obstructive pulmonary disease
(COPD) board; is on the Novartis and Almirall COPD drug development boards; is
on the Takeda COPD & asthma studies board; is on the GlaxoSmithKline trial
design board; is on the Cipla inhaler design board; has received consultancy fees
from AstraZeneca, Almirall, Vectura, Actelion, and Genentech; has received
research support from AstraZeneca, Novartis, Almirall, Merck, Takeda, Glax-
oSmithKline, Hoffmann la Roche, Actelion, Aeras, Chiesi, Sanoﬁ-Aventis,
Cephalon, and Teva; has received lecture fees from AstraZeneca, Novartis,
Takeda, GlaxoSmithKline, Chiesi, Cipla, Menarini, and ALK; has received pay-
ment for developing educational presentations from PeerVoice; is on the ICON
study oversight steering committee; and reports personal fees for lectures,
consulting, and advisory board membership and grants to his institution for
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Novartis, Takeda, and ICON; personal fees for consulting from Actelion, Astra-
Zeneca, Almirall, Genentech, and Vectura; personal fees for lectures from ALK,
AstraZeneca, Chiesi, Cipla, Glaxo SmithKline, Menarini, Novartis, and Takeda;
personal fees for educational materials from PeerVoice; and grants to his institution
for participation in clinical trials sponsored by Actelion, Aeras, Almirall,
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FEV1(0-3h)- FEV1 within 3 hours of tiotropium plus maintenance
therapy
HFA-MDI- Hydroﬂuoroalkane metered-dose inhalerHR- Hazard ratio
ICS- Inhaled corticosteroidLABA- Long-acting b2-agonist
MMRM- Restricted maximum likelihood-based repeated
measures
OR- Odds ratioREML- Restricted maximum likelihood
TALC- Tiotropium Bromide as an Alternative to Increased
Inhaled Glucocorticoid in Patients Inadequately
Controlled on a Lower Dose of Inhaled Corticosteroidphenotype; Cox regression modeling supported a beneﬁcial
effect of tiotropium on exacerbations, independent of IgE
levels or eosinophil counts. Numerical improvements in the
7-question Asthma Control Questionnaire (ACQ-7)
responder rate with tiotropium versus placebo were observed
in T2high and T2low patients; logistic regression modeling
provided further evidence for improvement in ACQ-7
responder rates with tiotropium, independent of IgE levels or
eosinophil counts.
CONCLUSIONS: The results of our exploratory analyses
suggest that the improvements seen with tiotropium Respimat as
add-on to ICS – LABA in patients with symptomatic asthma on
lung function, exacerbation risk, and symptom control are in-
dependent of T2 phenotype.  2017 The Authors. Published
by Elsevier Inc. on behalf of the American Academy of Allergy,
Asthma & Immunology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/). (J Allergy Clin Immunol Pract 2018;6:923-35)
Key words: Allergy; Asthma; Tiotropium Respimat; T2 status;
Eosinophil; IgE; Subgroup analysis
Asthma affects around 300 million people worldwide,1 and at
least 40% of individuals diagnosed with asthma remain symp-
tomatic despite treatment with inhaled corticosteroids (ICSs) as
monotherapy or in combination with long-acting b2-agonists
(LABAs). Failure to control asthma symptoms increases the risk
of serious asthma-related events such as exacerbations,2-4 whichCephalon, Chiesi, Glaxo SmithKline, Hoffman la Roche, Merck,
eda, TEVA, and Sanoﬁ-Aventis outside the submitted work; and is a
e Board of the Global Initiative for Asthma. M. Vandewalker has
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rticipated on advisory boards for Avontec, Boehringer Ingelheim,
/Schering-Plough, GlaxoSmithKline, Janssen-Cilag, Meda, MSD,
, Novartis, Regeneron, Revotar, Roche, Sanoﬁ-Aventis, Sandoz-
and UCB/Schwarz-Plough; has received research support from
Forschungsgesellschaft, Land Mecklenburg-Vorpommern,
line, and MSD; and has received lecture fees from AstraZeneca,
yer, Bencard Allergie, Bionorica, Boehringer Ingelheim, Chiesi,
g-Plough, GlaxoSmithKline, Janssen-Cilag, LETI, MEDA, Merck,
pharma, Novartis, Nycomed/Altana, Pﬁzer, Revotar, Sandox-Hexal,
Teva, UCB/Schwarz-Pharma, and Zydus/Cadila. H. Schmidt,
d P. Moroni-Zentgraf are employed by Boehringer Ingelheim.
stjens has received research support from Boehringer Ingelheim and
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patients and/or health care systems,5-8 and may contribute to the
accelerated decline in lung function that occurs over time in all
patients with asthma.9 Additional treatment options are therefore
needed. The clinical efﬁcacy and safety of tiotropium, a once-
daily long-acting anticholinergic bronchodilator (delivered via
the Respimat Soft Mist inhaler; Boehringer Ingelheim Pharma
GmbH & Co. KG, Ingelheim am Rhein, Germany) as add-on to
ICS or ICS plus LABA maintenance therapy, has been demon-
strated in a large clinical program involving more than
6000 patients aged 1 to 75 years and with varying asthma
severities.10-20 Consequently, treatment with tiotropium Respi-
mat has been included in the latest (2016) Global Initiative for
Asthma treatment strategy as an add-on option at step 4 or 5 for
patients aged 12 years or older with a history of exacerbations.21
There is a signiﬁcant allergic component to asthma in a large
proportion of patients.21 Patients with elevated T2 inﬂammatory
cytokines associated with eosinophilic inﬁltration (such as IL-5
and IL-13) are classiﬁed with T2high asthma.
22,23 For these pa-
tients, biologic treatment options include anti-IgE (omalizumab)
and antieIL-5 (mepolizumab and reslizumab).22,24,25 However,
eligibility for these treatments is determined on the basis of
biomarkers and this phenotyping may involve additional clinic
visits. In addition, these medications are applicable to a limited
subpopulation of patients with asthma only and are costly. To
reduce these additional costs, it is therefore beneﬁcial if safety
and efﬁcacy can be demonstrated irrespective of allergic status
and additional phenotyping before treatment. Here, we describe
the results of exploratory analyses to examine whether responses
to tiotropium were inﬂuenced by patients’ allergic and/or T2
status, in data from these 4 phase III trials in patients with
symptomatic asthma. Please see Video 1 (available in this article’s
Online Repository at www.jaci-inpractice.org) for an overview of
trial rationale and ﬁndings.METHODS
Overview of the PrimoTinA-asthma and MezzoTinA-
asthma trials
Full details of the study designs, methodologies, and main results
from the 4 trials have been published previously.13,14 The trials were
carried out in accordance with the Declaration of Helsinki and Good
Clinical Practice, and all participating patients provided written,
informed consent.Novartis; has been a principal investigator with grants to the University Medical
Center Groningen from Boehringer Ingelheim and Pﬁzer, and has served, on behalf
of his institution, on advisory boards for Boehringer Ingelheim and Pﬁzer. In the
past year, his institution has received similar funding from Almirall, AstraZeneca,
Chiesi, GlaxoSmithKline, Novartis, Takeda, and Teva.
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MezzoTinA-asthma were 2 pairs of replicate phase III, randomized,
double-blind, placebo-controlled, parallel-group studies assessing the
efﬁcacy and safety of tiotropium add-on therapy (5 mg in
PrimoTinA-asthma and 5 mg and 2.5 mg in MezzoTinA-asthma) in
patients with severe symptomatic asthma or moderate symptomatic
asthma, respectively.13,14
Brieﬂy, in PrimoTinA-asthma (NCT00772538 and
NCT00776984),13 following a 4-week screening period, patients were
randomized 1:1 to receive once-daily tiotropium 5 mg (2  2.5 mg) or
matching placebo each morning as add-on to ICS (800 mg bude-
sonide or equivalent) plus LABA with or without other maintenance
therapies for 48 weeks.
In the double-dummy MezzoTinA-asthma studies (NCT01172808
and NCT01172821),14 patients were randomized 1:1:1:1 following a 4-
week screening period to once-daily tiotropium 5 mg (evening, 2  2.5
mg), once-daily tiotropium 2.5 mg (evening, 2  1.25 mg), twice-daily
salmeterol 50 mg (morning, 2  25 mg; evening, 2  25 mg; via hydro-
ﬂuoroalkane metered-dose inhaler), or placebo (identical devices in a
double-dummy design), each as add-on to ICS (400-800 mg budesonide
or equivalent) for 24 weeks.
In all trials, tiotropium or placebo was administered as mainte-
nance therapy with ICS as monotherapy or in combination with
other controllers; therefore, patients in the “placebo” arm not only
received placebo but also continued to receive background treat-
ment. Open-label salbutamol (albuterol) metered-dose inhalers were
provided as rescue medication.
Study population
Patients aged 18 to 75 years with a 5-year or more history of
asthma (PrimoTinA-asthma) or a 3-month or more history of
asthma (MezzoTinA-asthma) were enrolled. An initial asthma
diagnosis before the age of 40 years and symptomatic disease, with a
7-question Asthma Control Questionnaire (ACQ-7) mean score of
1.5 or more, were required.26 The main exclusion criteria were
chronic obstructive pulmonary disease or serious unstable coexisting
illnesses.
Study end points
PrimoTinA-asthma: Coprimary lung function end points were
peak FEV1 response within 3 hours (FEV1(0-3h)) of tiotropium (plus
maintenance therapy) and trough FEV1 response, measured at the
end of the dosing interval (24 hours postdrug), 10 minutes before
the next dose, at week 24. The third coprimary end point, evaluated
from the 48-week pooled data from the 2 trials, was time to ﬁrst
severe asthma exacerbation. All coprimary end points were met.
Secondary end points included time to ﬁrst episode of asthma
worsening (prespeciﬁed as any asthma exacerbation) over 48 weeks
and ACQ-7 mean score.
MezzoTinA-asthma: Coprimary end points were peak FEV1(0-3h)
response (change from baseline) and trough FEV1 response at the
end of the 24-week treatment period. The third coprimary end point
was the ACQ-7 responder rate at week 24 in the pooled data from
the 2 trials. All coprimary end points were met. Secondary end
points included time to ﬁrst severe asthma exacerbation and time to
ﬁrst episode of asthma worsening over 24 weeks, in the pooled data.
In all trials, asthma exacerbation was deﬁned as a progressive
increase in 1 or more asthma symptom (ie, shortness of breath,
cough, wheezing, chest tightness) beyond the individual’s usual daily
asthma symptoms and lasting for at least 2 days, and/or a decrease in
best morning peak expiratory ﬂow of 30% or more from their meanDownloaded for Anonymous User (n/a) at Rijksuniversiteit Gron
For personal use only. No other uses without permission.morning peak expiratory ﬂow on 2 or more consecutive days. For an
exacerbation to be classed as severe, the above criteria must have
been met and the exacerbation must have required the initiation or
at least doubling of systemic (including oral) corticosteroids for at
least 3 days.
The analysis of adverse events was based on the concept of
treatment-emergent adverse events, that is, all adverse events that
were reported after the ﬁrst dose of study medication in the treat-
ment period and within 30 days after the last dose of study
medication.
For completeness, we show data for tiotropium 5 mg, tiotropium
2.5 mg, salmeterol, and placebo; however, to be concise, we do not
discuss salmeterol in this article.
Analyses of PrimoTinA-asthma and MezzoTinA-
asthma data by T2 status
Exploratory analyses of responses to treatment according to
markers of T2 status at baseline (total serum IgE levels and blood
eosinophil counts) were performed using 2 data pools: data from the
2 PrimoTinA-asthma trials and data from the 2 MezzoTinA-asthma
trials. For these exploratory analyses, all randomized patients who
took at least 1 dose of trial drug were included. Analyses from both
data pools were not powered for inferential conclusions; hence, P
values presented in this article must be considered nominal at the
5% alpha level and conclusions are exploratory in nature.
As is standard for subgroup analyses of clinical trial results,
categorization of the continuous parameters, total serum IgE levels
and blood eosinophil counts, was performed to analyze the treat-
ment effect within each subgroup category as well as the interaction
of treatment and subgroup. Such analyses were prespeciﬁed for both
the PrimoTinA-asthma data pool and the MezzoTinA-asthma data
pool for all end points in question, before unblinding of the indi-
vidual trials (except for analysis of ACQ-7 responders via logistic
regression, which was added post hoc). Models similar to the primary
analyses of the trials were used, appropriate to the end point
analyzed, that is, Cox regression for time-to-event end points, lo-
gistic regression for binary end points, and a restricted maximum
likelihoodebased approach of a mixed model for repeated measures
(MMRM) for continuous end points. For categorization, a patient’s
T2 status was assessed in relation to both serum IgE levels, catego-
rized as above or below 430 mg/L (equivalent to 179.2 IU/L), and
selected according to deﬁned normal ranges27 and clinician judg-
ment of allergic asthma, categorized as “Yes” or “No.” In addition,
blood eosinophil counts categorized by levels above or below 0.6 
109/L, selected according to deﬁned normal ranges,27 were used as a
putative indicator of eosinophilic asthma phenotype.
In addition to categorical subgroup analysis, modeling using
continuous variables, such as serum IgE levels and blood eosinophil
counts, was performed over the whole range of the parameter values.
For those analyses, no categorization of serum IgE or blood eosin-
ophils was necessary. Treatment effects obtained from the modeling
are presented over a range of values: total serum IgE from 2 to 2000
mg/L and blood eosinophils from 0.05 to 2.00  109/L.
In the following sections, the analyses are described in more detail
for each type of end point.
Peak FEV1(0-3h) and trough FEV1. Categorical subgroup
analyses of peak FEV1(0-3h) and trough FEV1 were performed using a
restricted maximum likelihoodebased MMRM approach, which
included “treatment,” “study,” “visit,” and “treatment-by-visit” as
ﬁxed, categorical effects, and “baseline” and “baseline-by-visit” asingen from ClinicalKey.com by Elsevier on June 05, 2018.
 Copyright ©2018. Elsevier Inc. All rights reserved.
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and a spatial power structure was used to model the within-patient
errors. The Kenward-Roger approximation was used to estimate
the denominator degrees of freedom. The treatment difference was
measured by calculating adjusted means and 95% CIs within sub-
group categories. An interaction P value was obtained via a separate
MMRM model that additionally included “subgroup” and “treat-
ment-by-subgroup” interaction terms, and assessed by a t test. In
addition, the MMRM model was applied throughout the range of
continuous serum IgE levels and blood eosinophil counts (log
values), modeled as linear continuous effects including the interac-
tion with treatment, to obtain the treatment difference and respec-
tive 95% CIs.
Time to first severe exacerbation and asthma wor-
sening. Categorical subgroup analyses of time to ﬁrst severe
exacerbation and time to ﬁrst episode of asthma worsening were
performed using Cox regression analysis. The regression model
included “treatment” and “study” as effects. The treatment effect was
measured by calculating hazard ratios (HRs) and 95% CIs within
subgroup categories. The validity of the proportional hazards
assumption, presumed in Cox regression, was checked graphically
through Kaplan-Meier plots and plots of Schoenfeld residuals. All
included patients were analyzed from start of treatment until ﬁrst
occurrence of the event (severe asthma exacerbation, worsening of
asthma). A patient who did not experience an event during the
treatment period was censored at the end of the treatment period.
An interaction P value was obtained via a separate Cox regression
that additionally included “subgroup” and “treatment-by-subgroup”
interaction terms, and was assessed by chi-square testing. In addi-
tion, the Cox regression model was applied throughout the range of
serum IgE levels and blood eosinophil counts (log values), modeled
as linear continuous effects including the interaction with treatment,
to obtain HRs and respective 95% CIs.
ACQ-7 responder rate. Categorical subgroup analyses of
ACQ-7 responder rate were performed using a logistic regression
that included “treatment” and “study.” Patients were deﬁned as re-
sponders if an improvement of 0.5 or more in the ACQ-7 mean
score (the minimum clinically important difference26) was observed.
The treatment effect was measured by calculating odds ratios (ORs)
and 95% CIs within subgroup categories. An interaction P value was
obtained via a separate logistic regression that additionally included
“subgroup” and “treatment-by-subgroup” interaction terms, and was
assessed by chi-square testing. In addition, the logistic regression
model was applied throughout the range of serum IgE levels and
blood eosinophil counts (log values), modeled as linear continuous
effects including the interaction with treatment, to obtain ORs and
respective 95% CIs. All analyses were conducted using SAS v9.4
(SAS Institute Inc, Cary, NC).
RESULTS
Across the PrimoTinA-asthma trials, 912 patients received at
least 1 dose of study medication. Total serum IgE levels were
more than 430 mg/L in 391 patients (42.9%), blood eosinophil
counts were more than 0.6  109/L in 189 patients (20.7%),
and 559 patients (61.3%) were considered to have allergic
asthma according to clinician judgment (Table I).
In the MezzoTinA-asthma trials, 2100 patients received at
least 1 dose of study medication. Total serum IgE levels were
more than 430 mg/L in 1297 patients (61.8%), blood eosinophilDownloaded for Anonymous User (n/a) at Rijksuniversiteit Gron
For personal use only. No other uses without permission.counts were more than 0.6  109/L in 429 patients (20.4%),
and 1361 patients (64.8%) were considered to have allergic
asthma according to clinician judgment (Table I).
Baseline demographic and disease characteristics
Baseline demographic and disease characteristics were
balanced between treatment groups within each trial (Table I).
Most patients were female (w60%); most patients had never
smoked (>75%). Mean age was higher in PrimoTinA-asthma
(53.0 years, compared with 43.1 years in MezzoTinA-asthma).
In the last 3 months before screening, concomitant leukotriene
modiﬁers had been taken by 22.5% and 10.1% of the patients in
PrimoTinA-asthma and MezzoTinA-asthma, respectively. A
concomitant diagnosis of allergic rhinitis was reported in 21.3%
and 28.9% of the patients in PrimoTinA-asthma and
MezzoTinA-asthma, respectively.
Efficacy
To evaluate whether tiotropium provided improvements in
lung function, exacerbations, and asthma control versus placebo
in both groups (those with T2high or T2low asthma), treatment
effects were analyzed (1) by comparing them in categorical
subgroups and (2) by representing them graphically across the
range of IgE levels and eosinophil counts. For completeness, see
Table E1 (available in this article’s Online Repository at www.
jaci-inpractice.org) for pooled overall analyses of PrimoTinA-
asthma and MezzoTinA-asthma with regard to lung function,
exacerbations, and asthma control versus placebo.
Peak FEV1(0-3h) and trough FEV1. For patients with se-
vere (PrimoTinA-asthma) or moderate (MezzoTinA-asthma)
asthma, peak FEV1(0-3h) and trough FEV1 responses were
signiﬁcantly improved with tiotropium versus placebo after 24
weeks’ treatment, with treatment differences ranging from 93
mL to 223 mL (Figures 1 and 2).
The results of the categorical subgroup analyses reveal that
these improvements in lung function with tiotropium versus
placebo were independent of serum IgE levels (above or below
430 mg/L), blood eosinophil counts (above or below 0.6  109/
L), and clinician judgment of allergic asthma (“Yes” or “No”) in
patients with severe (PrimoTinA-asthma) or moderate (Mezzo-
TinA-asthma) asthma (see Figures E1 and E2 in this article’s
Online Repository at www.jaci-inpractice.org).
Estimating the treatment differences across the range of IgE
levels and eosinophil counts demonstrated mean differences from
placebo in peak FEV1(0-3h) and trough FEV1 responses that were
consistently greater than 0 in patients with severe (PrimoTinA-
asthma) and moderate (MezzoTinA-asthma) asthma (Figures 1
and 2); that is, both doses of tiotropium were consistently su-
perior to placebo independent of baseline IgE levels or eosinophil
counts across the range of values.
Risk of severe exacerbations. Time to ﬁrst severe exac-
erbation for patients with severe (PrimoTinA-asthma) or mod-
erate (MezzoTinA-asthma) asthma was longer with tiotropium
versus placebo, with HRs ranging from 0.5 to 0.79 (Figure 3).
Categorical subgroup analyses demonstrated that this was in-
dependent of serum IgE levels, blood eosinophil counts, and
clinician judgment of allergic asthma in both patients with severe
(PrimoTinA-asthma) or moderate (MezzoTinA-asthma) asthma
(see Figure E3 in this article’s Online Repository at www.jaci-
inpractice.org).ingen from ClinicalKey.com by Elsevier on June 05, 2018.
 Copyright ©2018. Elsevier Inc. All rights reserved.
TABLE I. Baseline demographic and disease characteristics
Characteristic
PrimoTinA-asthma* MezzoTinA-asthma†
Tiotropium Respimat
5 mg QD (n [ 456)
Placebo Respimat QD
(n [ 456)
Tiotropium Respimat
5 mg QDz (n [ 517)
Tiotropium Respimat
2.5 mg QDz (n [ 519)
Salmeterol HFA-MDI
50 mg BIDx (n [ 541)
Placebojj
(n [ 523)
Sex, n (%)
Female 273 (59.9) 278 (61.0) 300 (58.0) 316 (60.9) 312 (57.7) 311 (59.5)
Male 183 (40.1) 178 (39.0) 217 (42.0) 203 (39.1) 229 (42.3) 212 (40.5)
Age (y), mean  SD 52.2  12.5 53.8  12.2 44.3  12.6 43.4  12.9 42.1  12.9 42.8  13.0
Body mass index (kg/m2), mean  SD 28.2  5.9 28.2  6.1 27.1  6.3 26.6  6.1 26.7  6.3 27.0  6.3
Smoking status, n (%)
Never smoked 340 (74.6) 352 (77.2) 420 (81.2) 437 (84.2) 446 (82.4) 453 (86.6)
Ex-smoker 116 (25.4) 104 (22.8) 97 (18.8) 82 (15.8) 95 (17.6) 70 (13.4)
Smoking history (pack-years), mean  SD 5.4  2.8 4.8  2.7 4.5  3.0 4.0  2.9 4.1  2.7 4.1  2.5
Median age at asthma onset (y) (range) 26.0 (0-44) 26.0 (0-39) 24.0 (0-40) 24.0 (0-40) 23.0 (0-48) 24.0 (0-39)
Duration of asthma (y), mean  SD 29.6  13.6 31.0  14.1 23.0  15.0 22.1  14.3 21.0  14.3 21.1  13.7
FEV1 % predicted, mean  SD{ 55.9  13.1 56.0  13.2 73.9  11.3 75.4  11.5 75.8  11.7 75.1  11.5
FVC % predicted, mean  SD{ 79.9  17.3 80.5  16.8 96.1  14.0 96.6  13.4 96.5  13.6 97.5  14.0
FEV1/FVC %, mean  SD{ 58.7  10.3 58.1  10.0 65.3  10.2 66.5  10.8 67.0  10.5 65.6  10.4
ICS dose of stable maintenance therapy
(mg/d),# mean  SD{
1191.7  525.0 1204.6  553.1 663.9  216.0 655.9  213.2 650.8  205.2 668.3  217.3
Potentially allergic asthma, n (%)
Serum IgE (>430 mg/L) 207 (45.4) 184 (40.4) 322 (62.3) 323 (62.2) 323 (59.7) 329 (62.9)
Blood eosinophils (>0.6  109/L) 102 (22.4) 87 (19.1) 105 (20.3) 104 (20.0) 111 (20.5) 109 (20.8)
Clinician judgment of allergic asthma
(yes)
276 (60.5) 283 (62.1) 329 (63.6) 332 (64.0) 356 (65.8) 344 (65.8)
Concomitant diagnosis of allergic rhinitis, n
(%)
103 (22.6) 91 (20.0) 141 (27.3) 154 (29.7) 155 (28.7) 157 (30.0)
Concomitant therapies of interest, n (%)**
Leukotriene modiﬁers 96 (21.1) 109 (23.9) 54 (10.4) 53 (10.2) 52 (9.6) 53 (10.1)
Systemic antihistamines 85 (18.6) 59 (12.9) 77 (14.9) 95 (18.3) 85 (15.7) 101 (19.3)
Antiallergic agents (excluding
corticosteroids)
18 (3.9) 19 (4.2) 24 (4.6) 31 (6.0) 26 (4.8) 27 (5.2)
Omalizumab 15 (3.3) 28 (6.1) 0 0 0 0
Immune modulatory agents and antibodies 4 (0.9) 4 (0.9) 4 (0.8) 5 (1.0) 3 (0.6) 6 (1.1)
BID, Twice daily; FVC, forced vital capacity; HFA-MDI, hydroﬂuoroalkane metered-dose inhaler; QD, once daily.
Treated set.
*Pooled data; add-on to ICS (800 mg budesonide or equivalent per day) þ LABA.
†Pooled data; add-on to ICS (400-800 mg budesonide or equivalent).
zPlus placebo HFA-MDI BID.
xPlus placebo Respimat QD.
jjPlacebo Respimat QD plus placebo HFA-MDI BID.
{Measured at visit 2 (randomization).
#Budesonide equivalent dose.
**Within the 3 mo before screening.
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FIGURE 1. Peak FEV1(0-3h) in PrimoTinA-asthma (A and B) and MezzoTinA-asthma (C-F), according to baseline serum IgE levels (Figure 1,
A, C, E) and blood eosinophil counts (Figure 1, B, D, F). Full analysis set. Adjusted mean difference (solid line) and 95% CIs (dotted line)
are presented.
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FIGURE 2. Trough FEV1 in PrimoTinA-asthma (A and B) and MezzoTinA-asthma (C-F), according to baseline serum IgE levels (Figure 2, A,
C, E) and blood eosinophil counts (Figure 2, B, D, F). Full analysis set. Adjusted mean difference (solid line) and 95% CIs (dotted line) are
presented.
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FIGURE 3. Risk of severe asthma exacerbation in PrimoTinA-asthma (A and B) and MezzoTinA-asthma (C-F), according to serum IgE
levels (Figure 3, A, C, E) and blood eosinophil counts (Figure 3, B, D, F). Full analysis set. HRs (solid line) and 95% CIs (dotted line) are
presented.
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CASALE ETAL 931Estimating the HRs across the range of IgE levels and eosinophil
counts in patients with severe asthma (PrimoTinA-asthma)
demonstrated that tiotropium 5 mg reduced the risk of severe ex-
acerbations versus placebo up to an IgE level of approximately 1250
mg/L (Figure 3, A) and across the range of eosinophil counts, with
an almost constant HR of approximately 0.8 (Figure 3, B).
In patients with moderate asthma (MezzoTinA-asthma), similar
modeling of HRs indicated that both doses of tiotropium reduced
the risk of severe asthma exacerbations versus placebo across the full
range of serum IgE levels and blood eosinophil counts measured
(Figures 3, C-F). HRs generally ranged from approximately 0.5 to
0.75 but were lower at the lower end of eosinophil counts
(w0.25  109/L) for the tiotropium 2.5 mg dose (Figure 3, F).
Time to first episode of asthma worsening. Both doses
of tiotropium increased the time to ﬁrst asthma worsening versus
placebo for patients with severe (PrimoTinA-asthma) or mod-
erate (MezzoTinA-asthma) asthma, with HRs of between 0.66
and 0.87 (Figure 4).
Categorical subgroup analyses showed that this was independent
of IgE levels, blood eosinophil counts, and clinician judgment of
allergic asthma for patients with severe asthma (PrimoTinA-asthma;
see Figure E4 in this article’s Online Repository at www.jaci-
inpractice.org). For patients with moderate asthma (MezzoTinA-
asthma), this was independent of blood eosinophil counts or
clinician judgment of allergic asthma, although in categorical sub-
group analysis an interaction P value of .04 (c2 test) was reported
for serum IgE levels in this case (Figure E4).
Estimating the HRs across the range of IgE levels and eosin-
ophil counts in patients with severe asthma (PrimoTinA-asthma)
demonstrated that tiotropium 5 mg reduced the risk of asthma
worsening versus placebo, independent of IgE levels, with an HR
consistently below 1 (Figure 4, A), and of eosinophil counts, with
an almost constant HR of approximately 0.70 (Figure 4, B).
In patients with moderate asthma (MezzoTinA-asthma), the
HRs across the range of IgE levels and eosinophil counts showed
that tiotropium 5 mg reduced the risk of asthma worsening versus
placebo except at the very lowest IgE levels (Figure 4, C) and blood
eosinophil counts (Figure 4, D). Similarly, tiotropium 2.5 mg also
reduced the risk of asthma worsening versus placebo in patients with
moderate asthma (MezzoTinA-asthma), independent of serum IgE
levels, with HRs of approximately 0.65 (Figure 4, E), and of blood
eosinophil counts. However, these HRs increased toward the higher
end of the scale but with wide 95% CIs (Figure 4, F).
ACQ-7 responder rate. In the pooled PrimoTinA-asthma
data, nominally signiﬁcant improvements in the ACQ-7
responder rate were observed with tiotropium 5 mg at week 24
(OR, 1.31; Figure 5) and at week 48 (OR, 1.67) versus placebo.
In the pooled MezzoTinA-asthma data, nominally signiﬁcant
improvements in the ACQ-7 responder rate (a coprimary end
point) were observed with tiotropium 5 mg (OR, 1.32) and 2.5
mg (OR, 1.33) at week 24 versus placebo (Figure 5).14
The results of the categorical subgroup analysis in patients with
severe asthma (PrimoTinA-asthma) demonstrated that tiotropium 5
mg was associated with numerical improvements in the ACQ-7
responder rate versus placebo at week 24 in T2high and T2low pa-
tients (see Figures E5,A, and E6,A, in this article’sOnline Repository
at www.jaci-inpractice.org), except in patients with blood eosinophil
counts of more than 0.6  109/L. Further improvements were
observed in the ACQ-7 responder rate with tiotropium at week 48Downloaded for Anonymous User (n/a) at Rijksuniversiteit Gron
For personal use only. No other uses without permission.(FiguresE5,B, andE6,B),whereas the responder rate remained stable
in the placebo arm with no further improvements at week 48.
In the categorical subgroup analyses of patients with moderate
asthma (MezzoTinA-asthma), there was a higher proportion of
ACQ-7 responders at week 24 with both doses of tiotropium
compared with placebo across subgroups (Figure E6, C). ORs for
tiotropium 5 mg and 2.5 mg were consistently above 1 in favor of
tiotropium versus placebo, and no interaction between treatment
and subgroups, IgE level, eosinophil count, or clinician assess-
ment of allergic asthma was observed (see Figure E7 in this ar-
ticle’s Online Repository at www.jaci-inpractice.org).
Estimating the ORs across the range of IgE levels and eosinophil
counts in patients with severe asthma (PrimoTinA-asthma) showed
that improvements in the ACQ-7 responder rate with tiotropium
versus placebo were independent of IgE values and eosinophil
counts (Figure 5, A and B). This was indicated by ORs consistently
above 1 across the range of IgE levels and eosinophil counts.
In patients with moderate asthma (MezzoTinA-asthma),
estimated ORs for tiotropium 5 mg were consistently in the re-
gion of 1.2 (Figure 5, C and D). Tiotropium 2.5 mg was asso-
ciated with an improvement in the ACQ-7 responder rate versus
placebo, except at the very lowest IgE levels (Figure 5, E) and
eosinophil counts (Figure 5, F).
Safety
Full safety data have been presented previously,13,14 albeit
brieﬂy: the incidence of adverse events was comparable between
treatment arms in PrimoTinA-asthma and MezzoTinA-asthma,
with asthma exacerbations, decreased peak expiratory ﬂow rate,
and nasopharyngitis the most frequently reported adverse events
(Table E2). The incidence of investigator-deﬁned drug-related
adverse events, adverse events leading to discontinuation, and
serious adverse events was low in all treatment arms, and no
deaths occurred.
DISCUSSION
The Global Initiative for Asthma (GINA) treatment strategy
includes tiotropium Respimat as an add-on therapy option in pa-
tients with a history of asthma exacerbations at step 4 or 5, with no
requirement for prior phenotyping. Because treatment decisions
should be optimized on the patient level, we aimed to provide
further scientiﬁc evidence in line with this guidance, thus enabling
physicians to make educated and individualized treatment decisions.
As a bronchodilator, the long-actingmuscarinic agonist tiotropium
reduces airﬂow obstruction by its antagonism of M3 receptors,
leading to airway smooth muscle relaxation. Airﬂow obstruction can
be observed across different asthma phenotypes, and therefore a
consistent beneﬁt of tiotropium can be expected. However, stimu-
lation ofmuscarinic receptors by acetylcholine has also been shown to
have proinﬂammatory effects. Because asthma is often associatedwith
a signiﬁcant allergic component, we explored whether responses to
tiotropium were inﬂuenced by patients’ allergic and/or T2 inﬂam-
matory status.Wepresent here comprehensive subgroup analyses that
investigate the inﬂuence of categorized and linear continuous baseline
parameters on the treatment effect of tiotropium. These analyses
suggest that the improvements versus placebo in lung function and
asthma control seen with once-daily tiotropium when added to ICS
(with or without other maintenance therapies) and administered via
Respimat are independent of T2 phenotype. Furthermore, the risk of
severe asthma exacerbations and asthma worsening is also reduced
versus placebo, independent of T2 phenotype.ingen from ClinicalKey.com by Elsevier on June 05, 2018.
 Copyright ©2018. Elsevier Inc. All rights reserved.
A B
DC
E F
FIGURE 4. Risk of asthma worsening in PrimoTinA-asthma (A and B) and MezzoTinA-asthma (C-F), according to serum IgE levels
(Figure 4, A, C, E) and blood eosinophil counts (Figure 4, B, D, F). Full analysis set. HRs (solid line) and 95% CIs (dotted line) are
presented.
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FIGURE 5. Logistic regression analysis of the ACQ-7 responder rate at week 24 in PrimoTinA-asthma (A and B) and MezzoTinA-asthma
(C-F), according to serum IgE levels (Figure 5, A, C, E) and blood eosinophil counts (Figure 5, B, D, F). Full analysis set. ORs (solid line) and
95% CIs (dotted line) are presented.
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add-on therapy option in patients with a history of asthma exac-
erbations at step 4 or 5, with no requirement for prior phenotyping,
as per GINA treatment strategy. In contrast, biologic agents that
target T2 factors such as eosinophils or IgE require phenotyping as
criteria for treatment. Taking the additional costs and resources
associated with biologic treatment options into account, it may be
appropriate to prescribe tiotropium before biologic agents, and our
data provide reassurance regarding the efﬁcacy and safety of tio-
tropium for patients with T2high and T2low asthma, independent of
concomitant controller therapy. However, optimal treatment de-
cisions should be individualized, and it is important to note that our
data do not provide head-to-head comparisons of tiotropium and
biologic agents.
Stimulation ofmuscarinic receptors by acetylcholine causes various
proinﬂammatory effects, the blockage of which by tiotropium could
account for its efﬁcacy in both T2high and T2low asthma. Therefore, it
is interesting to consider the results of our current analysis in the
context of nonclinical studies that have investigated the potential
antieT2-inﬂammatory effects of tiotropium. For example, tio-
tropium signiﬁcantly reduced inﬂammatory cell numbers and TH2
cytokine levels in an in vivo chronic asthmamodel28,29 and prevented
both antigen-induced eosinophilia and hyperreactivity of airway tis-
sues in antigen-challenged guinea pigs, at least in part via an anti-
inﬂammatory mechanism.30 Tiotropium prevents allergen-induced
goblet cell hyperplasia and mucus gland hypertrophy in guinea
pigs31 and IL-13einduced goblet cell differentiation in human airway
epithelial cells in vitro,32 which could contribute to the effect of tio-
tropium in preventing exacerbations.However, tiotropium could also
affect noneT2high-driven inﬂammation by various mechanisms.
Tiotropium has been shown to inhibit ex vivo neutrophil chemotaxis
from patients with chronic obstructive pulmonary disease, as well as
acting on alveolar macrophages to inhibit the release of reactive ox-
ygen species.33 Similar mechanisms may be responsible for the efﬁ-
cacy of tiotropium in patients with T2low asthma; neutrophilic
inﬂammation has been documented in patients with asthma34 and
may contribute to the disease pathogenesis via the release of proteases
and reactive oxygen species, both of which damage airways leading to
airway hyperresponsiveness and remodeling. In addition, neutrophilic
inﬁltration has been suggested as amarker of uncontrolled asthma and
is inversely correlated with FEV1.
34 Tiotropium has been shown
in vitro to reduce levels of IL-8 in a human bronchial epithelial cell
line, which may reduce not only neutrophil chemotaxis but also
bronchial smooth muscle cell chemotaxis and proliferation, known
effects of IL-8.35
Our studies do have some limitations. The percentage of patients
with recorded concomitant allergic rhinitis reported here was lower
than expected. This may have been due to underreporting of allergic
rhinitis. Although the assessment of allergic asthma status was
prompted by a speciﬁc “Yes”/“No” question in the case report form,
allergic rhinitis was recorded as part of the patients’ overall baseline
conditions and at the initiative of the individual investigator. How-
ever, we consider the patient population to be broadly representative
of those encountered in clinical practice because more than 90% of
those patients with allergic rhinitis recorded as a baseline condition
were also judged to have allergic asthma. In the absence of an agreed
deﬁnition for the T2 phenotype at the time of the study, the assess-
ment of “potentially allergic asthma” by a composite of serum IgE,
blood eosinophil levels, and “investigator judgment for allergic
asthma” is a necessary compromise, andmirrors the assessmentsmade
by physicians in clinical practice. The categories proposed were thoseDownloaded for Anonymous User (n/a) at Rijksuniversiteit Gron
For personal use only. No other uses without permission.commonly used in clinical practice, but, in retrospect, may be
imperfect. However, they are not dissimilar to those used in several
studies of biologic and antiallergy treatments.
Another potential limitation of this work is that subgroup analyses
performed by categorization of continuous baseline parameters (such
as biomarkers) require the selection of cutoff thresholds. We selected
cutoff thresholds for serum IgE and blood eosinophils on the basis of
reported upper limits of normal ranges.27 However, there is little
consensus on the most appropriate cutoff value for these biomarkers
and, in addition, small sample sizes might be obtained in some cutoff
groupings. Therefore, we modeled the inﬂuence of both parameters
on the treatment effect over the whole range of the parameter values
for peak and trough FEV1, time to ﬁrst severe exacerbation, time to
ﬁrst episode of asthma worsening, and the ACQ-7 responder rate.
Our modeling approach is a straightforward post hoc investigation to
support categorical subgroup analyses. Alternative approaches,
including mathematically more complex ones, can be found in the
literature.36-39 The advantage of such modeling is that no explicit
cutoff thresholds for subgroup categorization need to be selected and
defended a priori.These exploratory modeling analyses by serum IgE
and blood eosinophils in pooled data from the PrimoTinA-asthma
and MezzoTinA-asthma trials support the ﬁndings from the cate-
gorical subgroup analyses, demonstrating the efﬁcacy of tiotropium
independent of patients’ T2 status. Overall, our modeling analysis
supports the main results and conclusions and adds conﬁdence to the
beneﬁcial effect of tiotropium across awide range of biomarker values.
The 18-month recruitment period, along with the duration of
treatment (PrimoTinA-asthma, 48 weeks; MezzoTinA-asthma,
24 weeks), ensured that any seasonal variations in patients’
allergic responses were taken into account.
The ﬁndings from the analyses presented here are consistent
with those from the “Tiotropium Bromide as an Alternative to
Increased Inhaled Glucocorticoid in Patients Inadequately
Controlled on a Lower Dose of Inhaled Corticosteroid” (TALC)
study, in which the effect of tiotropium was independent of atopy,
IgE level, and sputum eosinophil count.40 The data presented here
expand on the evidence from the TALC study by showing a
treatment effect of tiotropium on patient-relevant end points
including exacerbations and asthma worsening, independent of
serum IgE levels or blood eosinophil counts. Furthermore, unlike
the TALC study, we assessed the effect of tiotropium on these end
points when added to ICS þ LABA treatment, as currently rec-
ommended by GINA21 and representative of clinical practice.
Finally, patients had more severe asthma, especially in the
PrimoTinA-asthma studies, compared with the TALC study.CONCLUSIONS
Results from the primary clinical trials showed that in patients
with moderate or severe symptomatic asthma despite ICS with or
without other maintenance therapies, once-daily tiotropium
Respimat improved airﬂow, reduced exacerbation risk, and
improved asthma symptom control. The results of our explor-
atory analyses suggest that these improvements are independent
of T2 status as assessed by IgE levels or eosinophil counts—
supported by categorical subgroup analysis and modeling of the
inﬂuence of these parameters on the treatment effects. Modeling
analyses like our approach prove valuable as a supportive tool in
subgroup analyses where there is no obvious a priori choice of
cutoff thresholds. Although our ﬁndings remain exploratory,
they support the potential use of tiotropium Respimat add-oningen from ClinicalKey.com by Elsevier on June 05, 2018.
 Copyright ©2018. Elsevier Inc. All rights reserved.
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–100 100 200 300 400
Adjusted mean
difference
(95% CI), mL
Number of 
patients P value
Clinician judgment: Yes
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
130 (68-192) 253
263
.001
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
58 (–64-180) 93
82
.35
Interaction 
P value||
Clinician judgment: No
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
76 (3-149) 169
166
.04
.21
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
115 (63-167) 318
336
.001
.70
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
148 (73-224) 169
167
.001
Overall:
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
110 (63-158) 422
429
.001
.74Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
102 (27-176) 197
180
.01
0
Favors tiotropiumFavors placebo
0–100 100 200 300 400
Adjusted mean
difference
(95% CI), mL
Number of 
patients P value
Interaction 
P value||
Favors tiotropium/salmeterolFavors placebo
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
168 (104-232)
197 (134-260)
166 (104-228)
176
184
200
180
.001
.001
.001
Overall:
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
185 (146-223)
223 (185-262)
196 (158-234)
481
492
510
492
.001
.001
.001
.97
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
193 (144-243)
237 (188-286)
214 (165-263)
301
305
306
309
.001
.001
.001
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
170 (127-213)
236 (193-279)
199 (156-241)
382
392
404
387
.001
.001
.001
.24
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
240 (152-328)
176 (88-264)
186 (100-273)
97
99
104
104
.001
.001
.001
Clinician judgment: No
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
180 (115-245)
243 (177-308)
215 (149-280)
177
177
179
172
.001
.001
.001
.62
Clinician judgment: Yes
189 (141-237)
213 (166-261)
187 (140-234)
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
304
315
331
320
.001
.001
.001
B
A
FIGURE E1. Peak FEV1(0-3h) responses at week 24 in *PrimoTinA-asthma (A) and †MezzoTinA-asthma (B), by T2 phenotype. BID, Twice
daily; HFA-MDI, hydrofluoroalkane metered-dose inhaler; QD, once daily. Some of these data have been published previously in Kerstjens
et al.E1 Reproduced according to the license terms of creative commons (https://creativecommons.org/licenses/by-nc-nd/4.0/). Full
analysis set. Treatment effect P values based on t test. *Pooled data; add-on to ICSs (800 mg budesonide or equivalent per day) þ
LABA. †Pooled data; add-on to ICSs (400-800 mg budesonide or equivalent). zPlus placebo HFA-MDI BID. xPlus placebo Respimat QD.
jjTreatment-by-subgroup interaction P value based on t test.
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difference
(95% CI), mL
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patients P value
Clinician judgment: Yes
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
91 (33-148) 252
263
.01
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
52 (–49-153) 93
82
.31
Interaction 
P value||
Clinician judgment: No
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
94 (28-160) 169
166
.01
.41
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
103 (53-152) 317
336
.001
.75
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
127 (61-194) 168
167
.001
.62
Overall: 
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
93 (50-137) 421
429
.001
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
89 (22-156) 197
180
.01
Favors tiotropiumFavors placebo
–100 100 200 300 400
Adjusted mean
difference
(95% CI), mL
Number of 
patients P value
Interaction 
P value||
Favors tiotropium/salmeterolFavors placebo
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
139 (72-206)
167 (101-233)
115 (50-180)
176
184
200
180
.001
.001
.001
.84
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
152 (98-205)
188 (135-242)
115 (61-168)
301
305
306
309
.001
.001
.001
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
137 (90-183)
185 (139-231)
115 (69-160)
382
392
404
387
.001
.001
.001
.51
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
182 (86-277)
158 (62-253)
111 (17-205)
97
99
104
104
.001
.01
.02
Clinician judgment: No
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
138 (68-208)
209 (139-279)
134 (64-204)
177
177
179
172
.001
.001
.001
.67
Clinician judgment: Yes
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
153 (101-204)
164 (113-215)
105 (54-155)
304
315
331
320
.001
.001
.001
0
Overall:     
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
146 (105-188)
180 (138-221)
114 (73-155)
481
492
510
492
.001
.001
.001
A
B
FIGURE E2. Trough FEV1 responses at week 24 in *PrimoTinA-asthma (A) and †MezzoTinA-asthma (B), by T2 phenotype. BID, Twice
daily; HFA-MDI, hydrofluoroalkane metered-dose inhaler; QD, once daily. Some of these data have been published previously in Kerstjens
et al.E1 Reproduced according to the license terms of creative commons (https://creativecommons.org/licenses/by-nc-nd/4.0/). Full
analysis set. Treatment effect P values based on t test. *Pooled data; add-on to ICSs (800 mg budesonide or equivalent per day) þ
LABA. †Pooled data; add-on to ICSs (400-800 mg budesonide or equivalent). zPlus placebo HFA-MDI BID. xPlus placebo Respimat QD.
jjTreatment-by-subgroup interaction P value based on t test.
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0.0625 0.25 1 4 16
HR vs. placebo
(95% CI)
Number of 
patients P value
Clinician judgment: Yes
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.84 (0.63-1.11) 274
281
.22
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.76 (0.48-1.20) 99
87
.24
Interaction 
P value||
Clinician judgment: No
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.75 (0.47-1.19) 179
173
.22
.68
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.82 (0.62-1.09) 342
354
.18
.75
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.74 (0.49-1.12) 175
177
.16
.17Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
1.09 (0.76-1.54) 205
182
.64
Favors placeboFavors tiotropium
0.0625 0.25 1 4 16
Favors placeboFavors tiotropium/salmeterol
HR vs. placebo
(95% CI)
Number of 
patients P value
Interaction 
P value||
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
0.87 (0.41-1.83)
0.50 (0.21-1.18)
0.81 (0.39-1.67)
190
192
212
188
.72
.11
.56
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
0.61 (0.33-1.11)
0.49 (0.26-0.94)
0.67 (0.37-1.20)
319
320
319
326
.11
.03
.18
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
0.65 (0.39-1.08)
0.41 (0.23-0.73)
0.62 (0.38-1.03)
406
411
422
410
.10
.01
.07
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
1.03 (0.30-3.54)
1.22 (0.37-3.99)
1.71 (0.57-5.11)
104
103
111
107
.97
.75
.34
Clinician judgment: No
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
1.57 (0.57-4.31)
1.12 (0.38-3.32)
0.80 (0.24-2.61)
186
185
183
178
.38
.84
.71
Clinician judgment: Yes
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
0.58 (0.34-1.00)
0.40 (0.22-0.73)
0.74 (0.46-1.21)
327
330
352
340
.049
.01
.24
.90
.27
.18
Overall: 
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.79 (0.62-1.00) 453
454
.03
Overall:
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
0.72 (0.45-1.14)
0.50 (0.30-0.84)
0.75 (0.48-1.18)
513
515
535
518
.16
.01
.21
B
A
FIGURE E3. Time to severe exacerbation in *PrimoTinA-asthma at week 48 (A) and †MezzoTinA-asthma at week 24 (B), by T2
phenotype. BID, Twice daily; HFA-MDI, hydrofluoroalkane metered-dose inhaler; QD, once daily. Calculation of the HR’s point estimate,
CI, and P value follow the confirmatory result of these studies as described by Kerstjens HA et al,E1 where some of these data have been
published previously. Reproduced according to the license terms of creative commons (https://creativecommons.org/licenses/by-nc-nd/4.
0/). Full analysis set. Treatment effect P values based on c2 test with df ¼ 1. *Pooled data; add-on to ICSs (800 mg budesonide or
equivalent per day) þ LABA. †Pooled data; add-on to ICSs (400-800 mg budesonide or equivalent). zPlus placebo HFA-MDI BID. xPlus
placebo Respimat QD. jjTreatment-by-subgroup interaction P value based on c2 with df ¼ 1.
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Clinician judgment: Yes
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.70 (0.57-0.87)
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.85 (0.59-1.21)
Clinician judgment: No
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.69 (0.51-0.93)
.89
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.65 (0.53-0.79)
.25
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.72 (0.54-0.97)
1.00Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.73 (0.57-0.95)
274
281
99
87
179
173
342
354
175
177
205
182
.01
.36
.01
.001
.03
.02
 Favors placeboFavors tiotropium
Favors placeboFavors tiotropium/salmeterol
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
.50
.001
.01
.04
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
.22
.17
.25
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
.41
.001
.01
.12
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
.18
.72
.77
Clinician judgment: No
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
.28
.05
.11
.94
Clinician judgment: Yes
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
190
192
212
188
319
320
319
326
406
411
422
410
104
103
111
107
186
185
183
178
327
330
352
340
0.88 (0.62-1.26)
0.45 (0.29-0.68)
0.60 (0.41-0.88)
0.84 (0.63-1.12)
0.82 (0.61-1.09)
0.85 (0.64-1.13)
0.90 (0.70-1.16)
0.60 (0.46-0.79)
0.70 (0.54-0.91)
0.70 (0.42-1.18)
0.92 (0.56-1.49)
 0.93 (0.58-1.49)
0.82 (0.57-1.17)
0.69 (0.48-1.00)
0.74 (0.51-1.07)
0.89 (0.67-1.19)
0.64 (0.47-0.87)
0.76 (0.56-1.01)
.42
.01
.06
4152.0
4152.0
HR vs. placebo
(95% CI)
Number of 
patients P value
Interaction 
P value||
HR vs. placebo
(95% CI)
Number of 
patients P value
Interaction 
P value||
Overall:
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.69 (0.58-0.82) 453
454
.001
Overall:
Tiotropium Respimat 5 µg QD‡
Tiotropium Respimat 2.5 µg QD‡
Salmeterol HFA-MDI 50 µg BID§
Placebo Respimat QD‡
.22
.001
.01
513
515
535
518
0.87 (0.69-1.09)
0.66 (0.52-0.84)
0.75 (0.60-0.94)
0.5 2
0.5 2
A
B
FIGURE E4. Time to asthmaworsening in*PrimoTinA-asthmaatweek48 (A) and†MezzoTinA-asthma atweek24 (B), by T2phenotype.BID,
Twicedaily;HFA-MDI, hydrofluoroalkanemetered-dose inhaler;QD, once daily. Someof thesedata havebeenpublishedpreviously inKerstjens
et al.E1 Reproduced according to the license terms of creative commons (https://creativecommons.org/licenses/by-nc-nd/4.0/). Full analysis
set. Treatment effect P values based onc2 testwith df¼ 1. *Pooled data; add-on to ICSs (800 mg budesonide or equivalent per day)þ LABA.
†Pooled data; add-on to ICSs (400-800 mg budesonide or equivalent). zPlus placeboHFA-MDI BID. xPlus placeboRespimatQD. jjTreatment-by-
subgroup interaction P value based on c2 test with df¼ 1.
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OR vs.
 placebo
(95% CI)
Number of 
patients P value
Clinician judgment: Yes
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
1.30 (0.93-1.81) 274
281 .13
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
0.84 (0.47-1.50) 99
87 .55
 ACQ-7 responder rate, PrimoTinA-asthma, Week 24*
Interaction 
P value†
Clinician judgment: No
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
1.36 (0.89-2.08) 179
173 .15
.85
Blood eosinophils: 0.6×109/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
1.43 (1.06-1.93) 342
354 .02
.10
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
1.41 (0.92-2.16) 175
177 .11
.87
Serum IgE: 430 µg/L
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
1.34 (0.90-2.01) 205
182 .15
Favors tiotropiumFavors placebo
Favors tiotropiumFavors placebo
OR vs.
 placebo
(95% CI)
Number of 
patients P value
Clinician judgment: Yes
Tiotropium Respimat 5 µg QD
Placebo Respimat QD
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FIGURE E5. ACQ-7 responder rate in PrimoTinA-asthma at weeks 24 and 48, by T2 phenotype. OR, Odds ratio; QD, once daily. Full
analysis set. Treatment effect P values based on c2 test with df ¼ 1. *Pooled data; add-on to ICSs (800 mg budesonide or equivalent per
day) þ LABA. †Treatment-by-subgroup interaction P value based on c2 test with df ¼ 1.
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FIGURE E6. ACQ-7 responder rate in PrimoTinA-asthma at week 24 (A) and week 48 (B), and in MezzoTinA-asthma at week 24 (C), by
T2 phenotype. BID, Twice daily; HFA-MDI, hydrofluoroalkane metered-dose inhaler; QD, once daily. *Patients with a 0.5 reduction in
the ACQ-7 score. †Plus placebo HFA-MDI BID. zPlus placebo Respimat QD. xPlacebo Respimat QD plus placebo HFA-MDI BID.
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(95% CI)
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ACQ-7 responder rate, MezzoTinA-asthma, Week 24*
Interaction 
P value§
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Tiotropium Respimat 2.5 µg QD†
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1.62 (1.18-2.23)
319
320
319
326
.04
.02
.01
Blood eosinophils: 0.6×109/L
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Salmeterol HFA-MDI 50 µg BID‡
Placebo Respimat QD†
1.23 (0.90-1.68)
1.32 (0.96-1.80)
1.23 (0.90-1.67)
327
330
352
340
.20
.09
.19
Overall:
Tiotropium Respimat 5 µg QD†
Tiotropium Respimat 2.5 µg QD†
Salmeterol HFA-MDI 50 µg BID‡
Placebo Respimat QD†
1.32 (1.03-1.70)
1.33 (1.03-1.71)
1.46 (1.13-1.87)
513
515
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.03
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FIGURE E7. ACQ-7 responder rate in MezzoTinA-asthma at week 24, by T2 phenotype. BID, Twice daily; HFA-MDI, hydrofluoroalkane
metered-dose inhaler; OR, odds ratio; QD, once daily. Full analysis set. Treatment effect P values based on c2 test with df ¼ 1. *Pooled
data; add-on to ICSs (400-800 mg budesonide or equivalent). †Plus placebo HFA-MDI BID. zPlus placebo Respimat QD. xTreatment-by-
subgroup interaction P value based on c2 test with df ¼ 1.
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TABLE E1. Pooled overall analyses of PrimoTinA-asthma and MezzoTinA-asthmawith regard to lung function, exacerbations, and asthma
control vs placebo
End point Trial pool Treatment effect, 95% CI, P value Model
Peak FEV1 PrimoTinA-asthma 5 mg Mean difference 0.110 (0.063-0.158),
P < .0001
MMRM model adjusted for treatment, study,
visit, Visit  Treatment, baseline,
Baseline  Visit (week 24 results)
Peak FEV1 MezzoTinA-asthma 5 mg Mean difference 0.185 (0.146-0.223),
P < .0001
MMRM model adjusted for treatment, study,
visit, Visit  Treatment, baseline,
Baseline  Visit (week 24 results)
Peak FEV1 MezzoTinA-asthma 2.5 mg Mean difference 0.223 (0.185-0.262),
P < .0001
MMRM model adjusted for treatment, study,
visit, Visit  Treatment, baseline,
Baseline  Visit (week 24 results)
Trough FEV1 PrimoTinA-asthma 5 mg Mean difference 0.093 (0.050-0.137),
P < .0001
MMRM model adjusted for treatment, study,
visit, Visit  Treatment, baseline,
Baseline  Visit (week 24 results)
Trough FEV1 MezzoTinA-asthma 5 mg Mean difference 0.146 (0.105-0.188),
P < .0001
MMRM model adjusted for treatment, study,
visit, Visit  Treatment, baseline,
Baseline  Visit (week 24 results)
Trough FEV1 MezzoTinA-asthma 2.5 mg Mean difference 0.180 (0.138-0.221),
P < .0001
MMRM model adjusted for treatment, study,
visit, Visit  Treatment, baseline,
Baseline  Visit (week 24 results)
Severe exacerbations PrimoTinA-asthma 5 mg HR 0.79 (0.62-1.00), P ¼ .0343 Cox proportional hazards model with
treatment as effect* (up to week 48)
Severe exacerbations MezzoTinA-asthma 5 mg HR 0.72 (0.45-1.14), P ¼ .1644 Cox proportional hazards model with
treatment as effect (up to week 24)
Severe exacerbations MezzoTinA-asthma 2.5 mg HR 0.50 (0.30-0.84), P ¼ .0084 Cox proportional hazards model with
treatment as effect (up to week 24)
Asthma worsening PrimoTinA-asthma 5 mg HR 0.69 (0.58-0.82), P < .0001 Cox proportional hazards model with
treatment as effect (up to week 48)
Asthma worsening MezzoTinA-asthma 5 mg HR 0.87 (0.69-1.08), P ¼ .2112 Cox proportional hazards model with
treatment as effect (up to week 24)
Asthma worsening MezzoTinA-asthma 2.5 mg HR 0.66 (0.52-0.84), P ¼ .0007 Cox proportional hazards model with
treatment as effect (up to week 24)
ACQ-7 responder PrimoTinA-asthma 5 mg OR 1.32 (1.01-1.73), P ¼ .0427 Fisher exact test (week 24)
ACQ-7 responder MezzoTinA-asthma 5 mg OR 1.32 (1.02-1.71), P ¼ .0348 Fisher exact test (week 24)
ACQ-7 responder MezzoTinA-asthma 2.5 mg OR 1.33 (1.03-1.72), P ¼ .0308 Fisher exact test (week 24)
ACQ-7, 7-question Asthma Control Questionnaire; HR, hazard ratio; MMRM, restricted maximum likelihood-based repeated measures; OR, odds ratio.
*Calculation of the HR’s point estimate, CI, and P value follow the conﬁrmatory result of these studies as described by Kerstjens et al.E1
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TABLE E2. Overall summary of patients with adverse events in PrimoTinA-asthma and MezzoTinA-asthma
n (%)
PrimoTinA-asthma* MezzoTinA-asthma†
Tiotropium Respimat
5 mg QD (n [ 456)
Placebo Respimat
QD (n [ 456)
Tiotropium Respimat
5 mg QDz (n [ 517)
Tiotropium Respimat
2.5 mg QDz
(n [ 519)
Salmeterol HFA-MDI
50 mg BIDx
(n [ 541) Placebojj (n [ 523)
Patients with any
AE
335 (73.5) 366 (80.3) 296 (57.3) 302 (58.2) 294 (54.3) 309 (59.1)
Patients with
investigator-
deﬁned drug-
related AEs
26 (5.7) 21 (4.6) 38 (7.4) 36 (6.9) 28 (5.2) 28 (5.4)
Patients with AEs
leading to
discontinuation
8 (1.8) 14 (3.1) 9 (1.7) 6 (1.2) 10 (1.8) 13 (2.5)
Patients with serious
AEs
37 (8.1) 40 (8.8) 11 (2.1) 12 (2.3) 11 (2.0) 14 (2.7)
AEs reported in
>5% of
patients,{ by
preferred term
Asthma
exacerbation
182 (39.9) 232 (50.9) 111 (21.5) 82 (15.8) 105 (19.4) 115 (22.0)
Decreased peak
expiratory ﬂow
rate
93 (20.4) 122 (26.8) 59 (11.4) 49 (9.4) 47 (8.7) 79 (15.1)
Nasopharyngitis 51 (11.2) 56 (12.3) 41 (7.9) 49 (9.4) 41 (7.6) 48 (9.2)
Upper respiratory
tract infection
21 (4.6) 16 (3.5) 19 (3.7) 27 (5.2) 41 (7.6) 41 (7.8)
Headache 29 (6.4) 33 (7.2) 8 (1.5) 18 (3.5) 6 (1.1) 14 (2.7)
Bronchitis 25 (5.5) 20 (4.4) 11 (2.1) 9 (1.7) 9 (1.7) 5 (1.0)
AE, Adverse event; BID, twice daily; HFA-MDI, hydroﬂuoroalkane metered-dose inhaler; QD, once daily.
Treated set; treatment period plus 30 days.
*Pooled data; add-on to ICSs (800 mg budesonide or equivalent per day) þ LABA.
†Pooled data; add-on to ICSs (400-800 mg budesonide or equivalent).
zPlus placebo HFA-MDI BID.
xPlus placebo Respimat QD.
jjPlacebo Respimat QD plus placebo HFA-MDI BID.
{Reported in >5% of patients in any treatment arm of the PrimoTinA-asthma or MezzoTinA-asthma trials.
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